A Safety Study of SGN-LIV1A in Breast Cancer Patients
Recruiting in Palo Alto (17 mi)
+39 other locations
Age: 18+
Sex: Female
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Seagen Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
Eligibility Criteria
Participant Groups
3Treatment groups
Experimental Treatment
Group I: LV MonotherapyExperimental Treatment1 Intervention
LV will be given at the recommended dose (at or below the monotherapy MTD determined in the LV dose escalation arm).
Group II: LV Dose EscalationExperimental Treatment1 Intervention
Group III: LV + TrastuzumabExperimental Treatment2 Interventions
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Oregon Health and Science UniversityPortland, OR
Cleveland Clinic, TheCleveland, OH
Virginia Piper Cancer InstituteMinneapolis, MN
University of MarylandBaltimore, MD
More Trial Locations
Loading ...
Who is running the clinical trial?
Seagen Inc.Lead Sponsor